Overview
- Editors:
-
-
Joseph Lustgarten
-
Sidney Kimmel Cancer Center, San Diego, U.S.A.
-
Yan Cui
-
Health Sciences Center, Louisiana State University, New Orleans, U.S.A.
-
Shulin Li
-
School of Veterinary Medicine, Louisiana State University, Baton Rouge, U.S.A.
Access this book
Other ways to access
Table of contents (18 chapters)
-
-
Cytokine Immune Therapy
-
-
-
- Chintana Chirathaworn, Yong Poovorawan
Pages 19-41
-
- Ian D. Davis, Kresten Skak, Naomi Hunder, Mark J. Smyth, Pallavur V. Sivakumar
Pages 43-59
-
- Sita Aggarwal, William Hansel, Rajasree Solipuram
Pages 61-74
-
-
- Jeffry Cutrera, Shulin Li
Pages 97-113
-
Cell-based Immune Therapy
-
Front Matter
Pages 116-116
-
-
- Archana Monie, Chien-Fu Hung, T.-C. Wu
Pages 133-157
-
- Lazar Vujanovic, Lisa H. Butterfield
Pages 159-172
-
-
-
- Faisal Razzaqi, Wesley M. Burnside, Lolie Yu, Yan Cui
Pages 207-223
-
Targeted Immune Therapy
-
Front Matter
Pages 226-226
-
- Danice E. C. Wilkins, William J. Murphy
Pages 227-239
-
-
- Jessica B. Katz, Alexander J. Muller, Richard Metz, George C. Prendergast
Pages 257-283
-
- Dinorah Friedmann-Morvinski, Zelig Eshhar
Pages 285-299
About this book
Stimulation of the immune system’s ability to control and destroy tumors cont- ues to be the goal of cancer immune therapy; but the scope has rapidly expanded; approaches are constantly updated; new molecules are continually introduced; and immune mechanisms are becoming better understood. This book has no intention of covering every aspect of immune therapy but rather focuses on the novelty of cancer immune therapy in an attempt to give readers an opportunity to absorb the new aspects of immune therapy from a single source. In this regard, three areas were selected: cytokine immune therapy, cell-based immune therapy, and targeted immune therapy. In each of these three sections, only the novel aspects of immune therapy were described instead of attempting to cover any historical achievement. In the first section, Cytokine Immune Therapy, the IL12 family, IL18, IL21, IL24, IL28, and IL29 were emphasized in regard to the an- tumor function and application in treating tumors. Most of these selected cyt- ines were discovered in last 10 years. In the second section, Cell-based Immune Therapy, the focus was engineering potent immune regulatory or effector cells such as dendritic cells, T cells, and stem cells. Cell engineering design is primarily based on the increased understanding of the interaction of tumor antigen-presenting cells, antigen- specific effector cells, and the tumor microenvironment.
Editors and Affiliations
-
Sidney Kimmel Cancer Center, San Diego, U.S.A.
Joseph Lustgarten
-
Health Sciences Center, Louisiana State University, New Orleans, U.S.A.
Yan Cui
-
School of Veterinary Medicine, Louisiana State University, Baton Rouge, U.S.A.
Shulin Li
